ErlySign Receives FDA Breakthrough Device Designation for Revolutionary Saliva-Based Oral Cancer Detection Test
Key Insights
ErlySign (search), a Nagpur-based biotech startup, has received US FDA Breakthrough Device Designation for its innovative saliva-based oral cancer detection kit, marking a significant regulatory milestone for early cancer detection technology.
The non-invasive diagnostic test requires only 2-5 ml of saliva and delivers results within 10-15 minutes, demonstrating 98% sensitivity and 100% specificity in clinical trials across approximately 1,000 patients.
The technology addresses India's significant oral cancer burden, where mouth cancer represents the second most common malignancy with over 143,000 new cases and nearly 80,000 deaths annually.
ErlySign (search), an innovative biotech startup from Nagpur, has achieved a significant regulatory milestone with the US Food and Drug Administration (FDA) granting Breakthrough Device Designation for its saliva-based oral cancer early detection kit. This designation underscores the potential of the company's technology to advance early cancer detection across international markets and represents a pivotal moment for non-invasive diagnostic solutions.
The FDA Breakthrough Device Designation is awarded to medical devices that demonstrate reasonable clinical evidence of providing more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases. Devices under this program benefit from accelerated development, prioritized regulatory review, and enhanced interaction with the FDA, enabling faster patient access to innovative medical technologies.
Revolutionary Diagnostic Technology
ErlySign (search)'s oral cancer detection test represents India's first saliva-based, non-invasive diagnostic solution designed to identify precancerous conditions even before visible tumors or lesions appear in the oral cavity, lips, tongue, throat, or larynx. The test requires only a 2-5 ml saliva sample and delivers results within 10-15 minutes, making it quick, painless, and easy to deploy across diverse healthcare settings.
"Receiving the US FDA Breakthrough Device Designation is a pivotal milestone for ErlySign (search)," said Shubhendra Singh Thakur, CEO & founder of ErlySign. "Beyond recognition, this designation enables priority regulatory review, closer and more interactive engagement with the FDA, and greater flexibility in clinical evidence requirements, significantly accelerating our path to market. It also strengthens our ability to engage with global healthcare systems and payers, helping ensure that a truly non-invasive, early cancer detection solution reaches patients faster, where it is needed most."
Clinical Validation and Performance
The technology has been clinically validated through large-scale, multi-city trials conducted in collaboration with Healthcare Global (search) Ltd. (HCG) and the Regional Cancer Hospital (search) (Rashtrasant Tukdoji Cancer Hospital), Nagpur. The studies, conducted across approximately 1,000 patients in Nagpur, Bengaluru, and Ranchi, demonstrated exceptional performance with 98% sensitivity and 100% specificity, validating the test's accuracy and effectiveness.
Dr Deovrat Begde, CSO & co-founder of ErlySign (search), emphasized the scientific significance of the achievement: "From a scientific and clinical standpoint, the Breakthrough Device Designation validates the robustness of our biomarker-driven approach and the depth of our clinical evidence. Detecting precancerous changes in a simple saliva sample before visible symptoms appear has long been a challenge in oncology. This recognition reinforces our belief that precision biology combined with non-invasive diagnostics can fundamentally change how cancers are detected, monitored, and managed globally."
Addressing Critical Healthcare Needs
India bears one of the world's highest burdens of oral cancer, with mouth cancer being the second most common malignancy in the country, accounting for over 143,000 new cases and nearly 80,000 deaths annually. Despite this significant disease burden, early detection remains a major challenge, with many cases diagnosed at advanced stages due to limited access to screening.
The cost-effectiveness of ErlySign (search)'s saliva-based test could support integrating early oral cancer screening into routine care, particularly for underserved and high-risk populations. This breakthrough technology addresses the critical gap in accessible, non-invasive screening methods that can detect precancerous conditions before they progress to advanced stages.
Future Prospects and Global Impact
With the US FDA Breakthrough Device Designation, ErlySign (search) strengthens its position in advancing early, non-invasive cancer detection and is actively exploring partnerships with healthcare providers and public health stakeholders to enable broader screening programs and pilot deployments globally. The designation not only validates the company's innovative approach but also opens pathways for accelerated regulatory approval and market access in international markets.